Taxus Cardium Pharmaceuticals Stock Book Value Per Share
| CRXMDelisted Stock | USD 0.0001 0.00 0.00% |
Taxus Cardium Pharmaceuticals fundamentals help investors to digest information that contributes to Taxus Cardium's financial success or failures. It also enables traders to predict the movement of Taxus Pink Sheet. The fundamental analysis module provides a way to measure Taxus Cardium's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Taxus Cardium pink sheet.
Taxus |
Taxus Cardium Pharmaceuticals Company Book Value Per Share Analysis
Taxus Cardium's Book Value per Share (B/S) can be calculated by subtracting liabilities from assets, and then dividing it by the total number of currently outstanding shares. It indicates the level of safety associated with each common share after removing the effects of liabilities. In other words, a shareholder can use this ratio to see how much he or she can sell the stake in the company in the event of a liquidation.
More About Book Value Per Share | All Equity Analysis
Book Value per Share | = | Common EquityAverage Shares |
Current Taxus Cardium Book Value Per Share | (0.1) X |
Most of Taxus Cardium's fundamental indicators, such as Book Value Per Share, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Taxus Cardium Pharmaceuticals is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
The naive approach to look at Book Value per Share is to compare it to current stock price. If Book Value per Share is higher than the currently traded stock price, the company can be considered undervalued. However, investors must be aware that conventional calculation of Book Value does not include intangible assets such as goodwill, intellectual property, trademarks or brands and may not be an appropriate measure for many firms.
CompetitionIn accordance with the recently published financial statements, the book value per share of Taxus Cardium Pharmaceuticals is about -0.096 times. This is 94.35% lower than that of the Biotechnology sector and 99.96% lower than that of the Health Care industry. The book value per share for all United States stocks is 100.0% higher than that of the company.
Taxus Book Value Per Share Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Taxus Cardium's direct or indirect competition against its Book Value Per Share to detect undervalued stocks with similar characteristics or determine the pink sheets which would be a good addition to a portfolio. Peer analysis of Taxus Cardium could also be used in its relative valuation, which is a method of valuing Taxus Cardium by comparing valuation metrics of similar companies.Taxus Cardium is currently under evaluation in book value per share category among its peers.
Taxus Fundamentals
| Return On Asset | -2.62 | |||
| Current Valuation | 881.11 K | |||
| Shares Outstanding | 64.93 M | |||
| Shares Owned By Insiders | 0.21 % | |||
| Number Of Shares Shorted | 150.25 K | |||
| Price To Book | 3.36 X | |||
| Price To Sales | 137.13 X | |||
| EBITDA | (458.68 K) | |||
| Net Income | (517.9 K) | |||
| Cash And Equivalents | 386.03 K | |||
| Cash Per Share | 0.01 X | |||
| Total Debt | 1.26 M | |||
| Debt To Equity | (1.01) % | |||
| Current Ratio | 0.08 X | |||
| Book Value Per Share | (0.1) X | |||
| Cash Flow From Operations | (1.13 M) | |||
| Short Ratio | 1.03 X | |||
| Earnings Per Share | (0.02) X | |||
| Target Price | 2.0 | |||
| Beta | -48.52 | |||
| Market Capitalization | 64 | |||
| Total Asset | 566.98 K | |||
| Retained Earnings | (114.05 M) | |||
| Working Capital | (3.8 M) | |||
| Current Asset | 30.78 K | |||
| Current Liabilities | 3.83 M | |||
| Net Asset | 566.98 K |
About Taxus Cardium Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Taxus Cardium Pharmaceuticals's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Taxus Cardium using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Taxus Cardium Pharmaceuticals based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out Trending Equities to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in interest. You can also try the Portfolio Anywhere module to track or share privately all of your investments from the convenience of any device.
Other Consideration for investing in Taxus Pink Sheet
If you are still planning to invest in Taxus Cardium Pharma check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Taxus Cardium's history and understand the potential risks before investing.
| Companies Directory Evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals | |
| Financial Widgets Easily integrated Macroaxis content with over 30 different plug-and-play financial widgets | |
| Bonds Directory Find actively traded corporate debentures issued by US companies | |
| Technical Analysis Check basic technical indicators and analysis based on most latest market data | |
| Portfolio Anywhere Track or share privately all of your investments from the convenience of any device | |
| Fundamental Analysis View fundamental data based on most recent published financial statements | |
| Price Ceiling Movement Calculate and plot Price Ceiling Movement for different equity instruments | |
| Options Analysis Analyze and evaluate options and option chains as a potential hedge for your portfolios | |
| CEOs Directory Screen CEOs from public companies around the world |